TissueTech has raised approximately $55.3 million in a new round of equity financing, according to a recently posed SEC filing. The Doral, Fla.-based company makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business). Money in the round came […]
Tissuetech
7 medtech stories we missed this week: March 31, 2017
This week we saw a few FDA 510(k) clearances and one of the 1st uses of a next-generation surgical robot in Asia. Here are 7 medtech stories we missed this week but thought were still worth mentioning: 1. Corindus touts first Asian use of next-generation robot Corindus Vascular Robotics announced in a March 31 press […]
TissueTech raises another $15m
TissueTech said today that it added another $15 million to its coffers, led by prior backers River Cities Capital Funds and Ballast Point Ventures. Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business). The company raised […]
OrthoSensor lands another $13M, closing $48M Series B round | Funding Roundup
OrthoSensor said it added $13 million to its Series B round, taking the total for the round to $48 million as it looks to capitalize on regulatory nods for its Verasense knee replacement device in the U.S. and Europe.
TissueTech fleshes out $10M equity round
TissueTech Inc. said it pulled down $10 million from a pair of venture capital shops to back its regenerative medicine subsidiaries, Bio-Tissue and Amniox Medical.
The equity round came from Ballast Point Ventures and River Cities Capital Funds, according to a press release.
Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (Bio-Tissue) and musculoskeletal conditions and wound care (Amniox Medical), according to the release.
Johnson & Johnson hits 52-week high on boosted earnings forecast | Wall Street Beat
Shares of Johnson & Johnson (NYSE:JNJ) surged to a 52-week high today after the healthcare conglomerate boosted its 2012 earnings forecast after reporting a solid, Street-beating quarter (and despite a nearly 18% bottom-line slide).
